Trial Profile
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2021
Price :
$35
*
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Alder Biopharmaceuticals
- 06 Jun 2021 Results of pooled analysis from 4 studies: (NCT01772524, NCT02275117, NCT02559895 (PROMISE-1), and NCT02974153 (PROMISE-2)) assessing the cardiovascular safety profile, CV risk in patients with migraine and mild to moderate CV risk factors, with few CV-related TEAEs and in few patients starting new or changing their dose of CV medication, presented at the 63rd Annual Scientific Meeting of the American Headache Society.
- 24 Jun 2019 Results published in the Cephalalgia
- 10 Sep 2017 Results of this trial and 2 other trials (refer CTP: 228412, 259778) were presented at the 2017 International Headache Society